Midatech Pharma undergoing strategic review
ImmunoPrecise Antibodies is expanding its therapeutic offerings as a global full-service antibody provider
Paradigm Biopharmaceuticals targets 2019-20 milestones for OA-MPS-BMEL pipeline
Only registered members can use this feature.
© Proactive Investors 2019.
Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority. Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.